Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-01-01

Study Completion Date

2020-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Objects: The purpose of this study was to observe the characteristics of morbidity, disease progression and therapeutic effects of 2019-novel coronavirus pneumonia patients with different clinical types.

Method: A single center, retrospective and observational study was used to collect COVID-19 patients admitted to Wuhan Infectious Diseases Hospital (Wuhan JinYinTan Hospital) from January 2020 to March 2020. The general information, first clinical symptoms, hospitalization days, laboratory examination, CT examination, antiviral drugs, immune enhancers, traditional Chinese medicine treatment and other clinical intervention measures were recorded, and the nutritional status and prognosis of the patients were recorded. confirm COVID-19 's disease progression, clinical characteristics, disease severity and treatment effects. To compare the characteristics of disease progression, clinical features, disease severity and therapeutic effect of different types of COVID-19.

Outcomes: The characteristics of disease progression, clinical features, disease severity and therapeutic effect of different types of COVID-19.

Conclusion: The characteristics of disease progression, clinical features and therapeutic effect of different types of COVID-19.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study for Novel Coronavirus Pneumonia (NCP)

NCT04283396

Novel Coronavirus Pneumonia

UNKNOWN

A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection

NCT04282902

Novel Coronavirus Pneumonia Pneumonia Pirfenidone

UNKNOWN PHASE3

A Study on the Prospective Cohort Library of COVID-19 in Southeran

NCT04342702

Follow-up COVID-19 Infectious Diseases +1 more

UNKNOWN

Observational Cohort of COVID-19 Patients in Hubei Province

NCT05615792

2019 Novel Coronavirus Disease

COMPLETED

A New Screening Strategy for 2019 Novel Coronavirus Infection

NCT04281693

Novel Coronavirus Infection Pneumonia

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Since December 2019, patients with unexplained pneumonia have appeared in some medical institutions in Wuhan, China. Nucleic acid testing was completed on January 10, 2020, which was confirmed to be caused by 2019-novel coronavirus. In 2020, the World Health Organization(WHO) named the virus 2019-novel coronavirus(2019-nCoV). The WHO announced that the pneumonia caused by 2019-nCoV is officially called COVID-19. Today, more than 70,000 cases have been confirmed and more than 2,000 patients have died.

At present, the epidemiological characteristics, laboratory indicators, imaging features and clinical treatment effects of COVID-19 should be reported, but the sample size is small. Large sample studies are still needed to further confirm COVID-19 's disease progression, clinical characteristics, disease severity and treatment effects, so as to provide a scientific basis for future clinical treatment. Therefore, it is particularly important to further review the relationship between the characteristics and prognosis of such patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pneumonia Caused by Human Coronavirus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

The ordinary COVID-19

Consistent with the diagnosis of ordinary COVID-19.

No interventions assigned to this group

The heavy COVID-19.

Consistent with the diagnosis of heavy COVID-19.

No interventions assigned to this group

The critical COVID-19

Consistent with the diagnosis of critical COVID-19

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 2019-nCov (SARA-Cov-2) nucleic acid positive detected by PCR.
2. Older than 18 years old and younger than 75 years old.
3. Meet the diagnostic criteria of COVID-19 for different types (including ordinary type, heavy type and critical type)

Exclusion Criteria

1. the age is less than 18 years old;
2. pregnant or lactating women;
3. severe underlying diseases, such as advanced malignant tumor, end-stage lung disease, etc.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No